Wojskowy Instytut Medyczny Panstwowy Instytut Badawczy
9
6
7
0
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 9 trials
22%
2 trials in Phase 3/4
0%
1 of 0 completed trials have results
Key Signals
Enrollment reporting
Analytics
Activity Timeline
Global Presence
Clinical Trials (9)
Randomized, Double-blind, Placebo-controlled Trial of the Efficacy and Safety of Tianeptine in the Treatment of Covid Fog Symptoms in Patients After COVID-19.
Role: lead
Ketoanalogues for Muscle Mass Loss in Nephrotic Syndrome
Role: lead
Evaluation of the efficacy and safety of dual biologic and/or small molecule therapy in patients with induction-resistant ulcerative colitis (RESPECT).
Role: lead
RemiRit - Personalized immunosuppressive therapy with rituximab in the treatment of ANCA associated vasculitis - a randomized, multicenter clinical trial
Role: lead
"MetCool ACS"- Metformin "Cooling" Effect on metformin-naive Patients Treated with PCI because of Acute Coronary Syndrome
Role: lead
Evaluation of the efficacy and safety of dual biological therapy in patients with refractory Crohn's disease resistant to induction (FLAMING).
Role: lead
PRObiotic Therapy Examining Combinatorial Therapeutics in Multiple Sclerosis - phase II, multicenter, randomised, open-label clinical trial.
Role: lead
A randomized trial comparing efficacy and safety of etanercept and methotrexate in giant cell arteritis (EFFECTA)
Role: lead
ITPP as an adjunctive treatment for progressive respiratory failure in COVID-19 and other pulmonary parenchymal infections [BREATH2]
Role: lead
All 9 trials loaded